Enterasense

First-ever ingestible capsule detecting UGIB


(

Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9

IMPROVING PATIENT OUTCOMES
COMPANY OVERVIEW

EnteraSense enters the market with an ingestible capsule capable of revolutionizing the detection of Upper Gastrointestinal Bleeding (UGIB)

IMPROVING PATIENT OUTCOMES
PROBLEM

IMPROVING PATIENT OUTCOMES
SOLUTION

PillSense accelerates the diagnostic outcome and provides better
patient stratification

Addresses Mortality

  • Early detection enables early intervention and thus clinical outcomes
  • Monitoring of the patient prevents escalation of rebleeds to critical status

Addresses Cost

  • Early detection reduces hospitalization admissions [up to 46%]
  • Early detection reduces length of stay between 30 – 50%

Addresses Inefficient use of Hospital Resources

  • Stratifying patients better to determine when intervention is required (within 24 – 72hrs)
  • Identifying high risk patients needing immediate intervention
  • Possibility to treat low risk patients as outpatients

OUR MISSION

IMPROVING PATIENT OUTCOMES
BENEFITS

IMPROVING PATIENT OUTCOMES
PATIENT PATHWAY

IMPROVING PATIENT OUTCOMES
ACCOMPLISHMENTS

Company Development

  • Product development is complete and is ready for commercial rollout
  • A Full ISO13485:2016 quality system is in place
  • Pre-clinical studies conducted successfully in the United States
  • De-Novo FDA Submission completed
  • Manufacturing process set up for early batch builds with an ability to scale quickly
  • Experienced team for commercial roll out in the USA and Tier-2 European countries in place

Intellectual Property

  • Core IP was obtained from Brigham & Women’s Hospital and Harvard Medical School.
  • Additional patent applications have been filed in 2020.

Awards and Funding

  • Obtained European Horizon 2020 Fast Track Innovation Grant
  • Investments sourced on the Fundable platform will be matched by Enterprise Ireland, up to $500K

IMPROVING PATIENT OUTCOMES
MEET THE TEAM

Donal Devery, Chief Executive Officer      
Senior executive with over 25 years of international business experience gained in multinational and start up businesses. Track record of developing new products with a number of granted patents. Has lead scale-up and commercialisation activities in both Europe and USA. An entrepreneurial individual with a good business instinct and a track record of achieving results. Has led and concluded a number of large commercial agreements including a recent commercial exit.

Daragh Sharkey,Chief Commercial Officer,
Daragh Sharkey is an experienced commercial MedTech executive who has many years of experience in driving commercial outcomes and success. Daragh has a Bsc from Trinity and a MSc in Business Technology. Daragh has completed a Diploma in International Sales management and has significant experience in establishing and managing Distribution networks across EU, USA and Asia.

Chiara DiCarlo, Chief Technology Officer
Chiara DiCarlo is an experienced Biomedical Engineer working in product development within the medical device sector. Chiara has led all technical activities and has driven the technology to its current status. Chiara is working on optical sensors development and is responsible for expanding the current IP portfolio of the company. Chiara has previously worked in Vysera Biomedical as a R&D Engineer with particular emphasis on biomaterials for synthetic valves in GI and urology applications. She received her MSc in Biomedical Engineer from the ULB (Belgium) and her MSc. In Nanotechnology and Tissue Engineering at the Politecnico of Milan.

David Collins, Chief Operating Officer
David has vast experience as a corporate engineering having worked previously with Micro Focus, the 7th largest global software provider. Responsible for the development of  innovative software solutions for global enterprises in data analytics and supply chain management. Formerly of HPE & HP has an extensive knowledge of establishing and managing supply chain networks on a global scale. An MBA Student of the National University of Galway Ireland.

Dr. Chris Thompson
Dr. Christopher Thompson is the Director of Developmental Endoscopy at Brigham and Women’s Hospital and an Instructor in Medicine at Harvard Medical School. He is also on staff at the Dana Farber Cancer Institute and Children’s Hospital Boston and is co-director of the DoD funded CIMIT Working Group on Endoscopic Surgery. Dr Thompson is also a serial entrepreneur having founded Beacon Endoscopy and GI Windows prior to EnteraSense. He acted as Chief Medical Officor for Beacon bringing the product to commercialization in collaboration with Covidien.

Dr. Marvin Ryou
Dr. Ryou received his MD degree from Harvard Medical School and completed advanced Clinical and Research fellowships at Brigham and Women’s Hospital and Massachusetts General Hospital, both teaching affiliates of Harvard Medical School. Dr. Ryou is currently a staff physician and advanced endoscopist at Brigham and Women’s Hospital, Harvard Medical School. Dr. Ryou has served as consultant to various medical device companies, including Covidien and Beacon Endoscopic, Inc. and he has founded GI Windows.

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.


Request Access

N

No updates yet.




%

No backers yet.




Quick Signup TBD

You must have an account to do this!


the startups.com platform

Copyright © 2019 Startups.com. All rights reserved.

Fundable is a software as a service crowdfunding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.